Spec table + per-test methodology available on the public COA page
6 Bach-y-RitaP
Third, beginning October 1, 2024, upon the expiration of device pass-through payment status for C1831, CMS packaged the payment for the costs of each of the devices described by C1831 into the payment for the costs related to the procedure with which each device is reported in the hospital claims data
These are rare but more likely in patients with pre-existing cardiovascular conditions
In one specific embodiment of the auris-acceptable controlled-release formulations described herein, the active agent is provided in a gel matrix, also referred to herein as auris-acceptable gel formulations, auris interna-acceptable gel formulations, auris media-acceptable gel formulations, auris externa-acceptable gel formulations, auris gel formulations, or variations thereof
Important Safety Information